Colorectal cancer (CRC) is one of the most common cancers globally and is associated with
a high rate of morbidity and mortality. A large proportion of patients with early stage CRC, who undergo
conventional treatments develop local recurrence or distant metastasis and in this group of advanced
disease, the survival rate is low. Furthermore there is often a poor response and/or toxicity associated
with chemotherapy and chemo-resistance may limit continuing conventional treatment alone.
Choosing novel and targeted therapeutic approaches based on clinicopathological and molecular features
of tumors in combination with conventional therapeutic approach could be used to eradicate residual
micrometastasis and therefore improve patient prognosis and also be used preventively. Peptide-
based vaccination therapy is one class of cancer treatment that could be used to induce tumorspecific
immune responses, through the recognition of specific antigen-derived peptides in tumor
cells, and this has emerged as a promising anti-cancer therapeutic strategy. The aim of this review was
to summarize the main findings of recent studies in exciting field of peptide-based vaccination therapy
in CRC patients as a novel therapeutic approach in the treatment of CRC.
Keywords: Peptide, vaccine, immunotherapy, colorectal cancer, treatment, clinicopathological.
van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 2014; 50(1)e34
Lindblad EB, Schønberg NE. Aluminum adjuvants: preparation, application, dosage, and formulation with antigen Vaccine Adjuvants 2010; 41-58.
Ebrahimnezhad S, Jazayeri M, Hassanian SM, Avan A. Current status and prospective regarding the therapeutic potential of natural autoantibodies in cancer therapy. J Cell Physiol 2017; 232(10): 2649-52.
Rights & PermissionsPrintExport